CoQ10 absortion is extremely poor, variously estimated as typically 1-3%. While a number of companies have attempted to market formulas claiming enhanced bioavilability, no studies have been performed to support most of these claims.

Any laboratory method for analyzing human plasma CoQ10 must be scientifically recognized as valid and reproducible. The analytical method used to evaluate the bioavailability of Jarrow Formulas’ Q-absorb (and subsequent clinical studies) is accepted by the International Association for Coenzyme Q10 and used by recognized Q researchers around the world.

Hence, the data in this study is reproducible.

Q-absorb represents an important development in enhancing the bioavaiability of CoQ10 by using normal lipid uptake mechanisms of the body.

This Study Confirms Effectiveness of Q-Sorb
Utilizing a coenzyme Q10 formulation (Jarrow Formulas® Q-absorb™) Italian scientists from the Lancisi Heart Institute and the University of Ancona investigated the effects of Jarrow Formulas® Q-absorb™ on chronic heart failure patients. The patients all began the study with impaired vasodilation when exercising. This dilation function is essential in order to allow increased blood and oxygen supply during physical activity. The diminution of this function results in angina (chest pain due to inadequate blood supply to the heart muscle) and reduced capacity for physical activity.

100 mg of CoQ10 from Q-absorb was given at each meal of the day, an approach that is superior to taking all 300 mg at one time. Patients showed improved heart functional capacity, enhanced vasodilation and a tripling of plasma Co-Q10 levels.

In sum, the study demonstrated that Q-absorb improves endothelial function in patients with ischemic heart disease and heart failure. The co-administration of Q-absorb and exercise therapy resulted in the greatest gains, with endothelial dysfunction being almost normalized.

These results were presented by Romualdo Berlardinelli, MD, FESC, of the Lancisi Heart Institute, Ancona, Italy, at the annual meeting of the American Heart Association held November 9-12, 2003 in Orlando, Florida.